financetom
Business
financetom
/
Business
/
Maintaining FY22 guidance of topline of over Rs 10,000 cr: Dixon Technologies’ Atul Lall
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Maintaining FY22 guidance of topline of over Rs 10,000 cr: Dixon Technologies’ Atul Lall
Mar 26, 2021 4:09 AM

Atul Lall, Managing Director of Dixon Technologies on Friday said that they will end FY21 with a revenue of around Rs 6,200-6,300 crore. Lall also said that they are maintaining FY22 guidance of over Rs 10,000 crore.

“Current financial year we are going to close at around Rs 6,200-6,300 crore which is a decent growth over last year’s revenue of almost Rs 4,400 crore. Similarly, we will have growth in profitability also. This is despite in Q1 because of the pandemic, it was a complete washout. In the forthcoming financial year, we are targeting very aggressive growth. I had already mentioned a number of Rs 10,000 crore plus in FY21-22 and a significant increase in the bottomline as well. So, we still stand by the same; possibility we will do even better,” he told CNBC-TV18.

Lall expects the margin to remain in the range of 4.4-4.5 percent going ahead on the back of the product mix. He is also expecting a 25-30 percent CAGR run-rate post FY22.

He said that commodity price rise is impacting the consumer durable companies.

However, Lall said, “We have two kinds of revenue streams. One is an OEM revenue stream wherein we work on a prescriptive basis. So, all price increases on the commodity side, we have been able to pass on to our principle because that is the way the contracts are drafted.”

He also said that for the current financial year, Dixon Technologies has met the eligibility criteria on investment and revenue threshold for handset manufacturing PLI. However, they have not yet heard from the government.

Watch the video for more

(Edited by : Ajay Vaishnav)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Colombier Acquisition II to Pursue Business Combination With GrabAGun
Market Chatter: Colombier Acquisition II to Pursue Business Combination With GrabAGun
Jan 6, 2025
06:58 AM EST, 01/06/2025 (MT Newswires) -- Colombier Acquisition Corp (CLBR) has agreed to merge with GrabAGun in a deal valuing the online weapons vendor at $150 million, Bloomberg reported Sunday, citing people familiar with the matter. Bloomberg reported that Colombier Chief Executive Omeed Malik also founded the investment firm 1789 Capital, which backs companies aligned with the American political...
DHT Holdings Purchases 0.9% of Outstanding Shares in December
DHT Holdings Purchases 0.9% of Outstanding Shares in December
Jan 6, 2025
06:53 AM EST, 01/06/2025 (MT Newswires) -- DHT Holdings ( DHT ) said Monday it has bought about 1.5 million of its shares at an average price of about $8.89 per share in December. The repurchased shares represent 0.9% of the company's outstanding shares. ...
BRIEF-Wuxi Biologics To Sell Assets Related To Vaccines Ireland Facility
BRIEF-Wuxi Biologics To Sell Assets Related To Vaccines Ireland Facility
Jan 6, 2025
Jan 6 (Reuters) - WuXi Biologics (Cayman) Inc ( WXIBF ): * ASSET TRANSACTION RELATED TO VACCINES IRELAND FACILITY * TOTAL CONSIDERATION OF APPROXIMATELY US$500 MILLION * CO AND WUXI VACCINES IRELAND ENTERED INTO AGREEMENT WITH MSD INTERNATIONAL * WUXI VACCINES IRELAND TO SELL ALL PROPERTY AND ASSETS RELATED TO VACCINES IRELAND FACILITY Further company coverage: ...
WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million
WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million
Jan 6, 2025
Jan 6 (Reuters) - WuXi Biologics ( WXIBF ) said on Monday its unit, WuXi Vaccines Ireland, will sell its vaccine facility in Ireland to Merck ( MRK ) for about $500 million. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved